efficacy

You have access
The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma
Jia Lu, Ting Li, Zhichao Liao, Hui Yu, Yongtian Zhao, Haixiao Wu, Zhiwu Ren, Jun Zhao, Ruwei Xing, Sheng Teng, Yun Yang, Xiangchun Li, Kexin Chen, Jonathan Trent and Jilong Yang

Cancer Biology & Medicine June 2022, 19 (6) 910-930; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0270
You have access
Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events
Rilan Bai, Naifei Chen, Xiao Chen, Lingyu Li, Wei Song, Wei Li, Yuguang Zhao, Yongfei Zhang, Fujun Han, Zheng Lyu and Jiuwei Cui

Cancer Biology & Medicine November 2021, 18 (4) 1118-1133; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0052
You have access
Pemetrexed Monotherapy and Pemetrexed Plus Platinum Combination Therapy as Non-First-Line Treatments for Advanced Non-Small Cell Lung Cancer
Fang WANG, Gui-fang GUO, Hui-juan QIU, Xu-xian CHEN, Pi-li HU, Fei-fei ZHOU, Wen-zhuo HE, Bei ZHANG and Liang-ping XIA

Clinical Oncology and Cancer Research December 2011, 8 (4) 235-241; DOI: https://doi.org/10.1007/s11805-011-0587-3

Main menu